Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SpyGlass PharmaSGP -0.59%12 EV-to-OCF is -13.07 as of Aug. 11, 2026. GuruFocus rates SGP with a GF Score™ of 12/100. Among 1,406 Biotechnology companies, SpyGlass Pharma ranks better than 85.42% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, SpyGlass Pharma's Enterprise Value is $608.63 Mil.
SpyGlass Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-46.56 Mil. Therefore, SpyGlass Pharma's EV-to-OCF for today is -13.07.
The historical rank and industry rank for SpyGlass Pharma's EV-to-OCF or its related term are showing as below:
SGP'
s EV-to-OCF Range Over the Past 10 Years
Min: -27.16 Med: 0 Max: -25.93
Current: -26.6
During the past 3 years, the highest EV-to-OCF of SpyGlass Pharma was -25.93. The lowest was -27.16. And the median was .
SGP's EV-to-OCF is ranked better than 85.42% of 1406
companies
in the Biotechnology industry
Industry Median: -3.515
vs SGP: -26.60
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SpyGlass Pharma's PE Ratio (TTM) for today is calculated as:
SpyGlass Pharma's share price for today is $25.07.
SpyGlass Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.981.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
SpyGlass Pharma EV-to-OCF Related Terms
SpyGlass Pharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for SpyGlass Pharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SpyGlass Pharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SpyGlass Pharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SpyGlass Pharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where SpyGlass Pharma's EV-to-OCF falls into.
SpyGlass Pharma's current Enterprise Value is $608.63 Mil.
SpyGlass Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SpyGlass Pharma (SGP) has a EV-to-OCF of -13.07 as of Aug. 11, 2026. According to the industry distribution chart, SpyGlass Pharma ranks #205 out of 1406 companies in the Biotechnology industry, placing it in the top 14.6%.
Is SpyGlass Pharma's EV-to-OCF too high?
SpyGlass Pharma's current EV-to-OCF is -13.07. Based on the distribution chart, SpyGlass Pharma ranks #205 out of 1406 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SpyGlass Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SpyGlass Pharma's EV-to-OCF compare to RIGL and NGNE?
According to the Biotechnology industry distribution chart, SpyGlass Pharma ranks #205 out of 1406 companies for EV-to-OCF. This places SpyGlass Pharma in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. SpyGlass Pharma's current EV-to-OCF is -13.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpyGlass Pharma stock overvalued right now?
SpyGlass Pharma (SGP) has a current EV-to-OCF of -13.07. The current EV-to-OCF is -13.07. SpyGlass Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For SpyGlass Pharma (SGP), the current EV-to-OCF is -13.07 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
12GF Score
Get the complete analysis for SGP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGP has been successfully added to your 
